ImmunoGen Inc. plans to offer and sell 13 million common shares in an underwritten public offering.
The company plans to grant underwriters an option to buy up to an additional 15% of the shares offered.
Net proceeds will be used to fund the company's operations, including research and development activities, clinical trial activities, manufacturing and supply of drug substance and drug products, commercialization preparation, acquisitions of new technologies, capital expenditures and working capital.
Jefferies, Leerink Partners and RBC Capital Markets are acting as joint book-running managers for the proposed offering. Canaccord Genuity is acting as co-manager for the proposed offering.